Extended follow-up (median 54.8 months) of a phase 3 RCT in 1579 patients with advanced HER2-negative gastric/GEJ adenocarcinoma: pembrolizumab plus chemotherapy vs placebo plus chemotherapy gave median OS 12.9 vs 11.5 months (HR 0.78); grade 3–4 related AEs 58.3% vs 49.3%.
RCTn = 1,579
Rha et al. Pembrolizumab plus chemotherapy as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: 4.5-year follow-up from the randomized phase III KEYNOTE-859 study